Alberta Regulator Sides with Aurora, Dismisses Curaleaf’s ATM Challenge

EDMONTON – The Alberta Securities Commission (ASC) dismissed Curaleaf Holdings‘ application to halt Aurora Cannabis‘s at-the-market (ATM) share-sale program, delivering a regulatory setback to the American Cannabis company’s hostile takeover campaign. The ruling confirmed that Aurora’s ATM program is compliant with securities laws.

Curaleaf had filed a complaint with the ASC to halt Aurora’s ATM share issuances, which it argued were dilutive and increased the cost of its takeover offer by over $11 million. The regulator declined to intervene. Aurora’s ATM program was publicly announced in February 2026, over six months before Curaleaf launched its hostile bid, as part of the company’s long-term international growth strategy.

The revised hostile bid, filed October 6, 2026, offers Aurora shareholders implied consideration of $5 [with a cap price of $6] per Aurora share, consisting of $1 in cash plus 0.4013 of a Curaleaf subordinate voting share with a bid expiry of December 4, 2026. Aurora’s board has unanimously rejected the offer, calling it inadequate and opportunistic.

Aurora is debt-free with a strong cash position, which it has highlighted as an advantage over Curaleaf’s heavily leveraged balance sheet. The company has also filed its own complaint with the ASC over what it describes as disclosure deficiencies in Curaleaf’s bid circular – gaps it argues could prevent Aurora shareholders from making a fully informed decision. In response to the hostile bid, Aurora’s special committee is actively exploring a range of alternatives that may offer greater value to shareholders, including a possible transaction with one or more third parties or remaining independent and executing its existing strategy.

The ASC’s ruling strips away one of the few arguments Curaleaf had for redirecting this takeover story toward Aurora’s own financial conduct. The ATM program predates the hostile bid by months; the regulator’s decision affirms that plainly. What remains on the table is a straightforward question of valuation:

Does an implied $5 per share fairly capture a debt-free, EU-GMP-certified medical Cannabis company with a global footprint that Curaleaf itself deemed valuable enough to pursue through a hostile campaign?

Aurora’s board says no, and the special committee is still looking for proof of a better alternative. With the bid open through December 4, there is time for a competing offer to surface, but Aurora shareholders are being asked to hold steady while that search plays out. That kind of patience carries its own cost.